Sep 02, 2026
Pipeline
TScan is developing a robust pipeline of T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer.
Title
Indications
Program (Targets)
Discovery
IND-enabling
Phase I
In vivo-engineered TCR-T cell therapies
Swipe left to show more
Swipe left to show more
Solid Tumors
Undisclosed
TSC-303-A02
(PRAME)
(PRAME)
Undisclosed
TSC-302-A02
(MAGEA4)
(MAGEA4)
Undisclosed
TSC-303-A24
(PRAME)
(PRAME)
Engineered TCR-T cell therapies
Swipe left to show more allowing data to mature. seeking strategic partnership
Swipe left to show more allowing data to mature. seeking strategic partnership
Hematologic Malignancies
AML, MDS
TSC-101
(HA-2)
(HA-2)
AML, MDS, ALL, NHL
TSC-102
(CD45)
(CD45)
Target-directed therapeutics
Swipe left to show more seeking strategic partnership
Swipe left to show more seeking strategic partnership
Autoimmunity
Ankylosing spondylitis and other HLA-B*27-associated diseases
Expanded Access Policy
TScan Therapeutics is focused on the development and potential commercialization of novel therapies to treat hematologic and oncologic malignancies, as well as other diseases.
At this time, TScan does not provide access to investigational products outside of clinical trials. We encourage patients to participate in clinical trials of our investigational therapies whenever possible, because clinical trials are designed, conducted, and monitored to ensure that the safety and efficacy are appropriately evaluated before they are submitted to regulatory agencies for review with the intent to make them more broadly available to patients.
You and your health care provider may learn more about our clinical trials by visiting www.clinicaltrials.gov and searching for TScan.
If you are a health care provider who is interested in learning more about one of our investigational therapies, or a physician with questions about participation in one of our clinical trials, please submit a request to medicalaffairs@tscan.com. The Company will acknowledge questions as soon as possible, usually within 5 business days of receipt.
TScan Therapeutics reserves the right to revise this expanded access policy at any time.